BioSpace News Archive

Humanetics Corporation (Humanetics) announced today that it has completed a phase 1 trial of the Company’s medical countermeasure for acute radiation syndrome (ARS), BIO 300 Oral Powder (NCT04650555).

Endo International plc (NASDAQ: ENDP) announced today that one of its operating companies, Par Pharmaceutical, Inc. (Par), has begun shipping the generic version of Pfizer’s Chantix® (varenicline), 0.5 mg and 1 mg tablets, following final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application.

Transgene publishes its financial results for the six-month period ended June 30, 2021, and provides an update on the progress of its portfolio of clinical-stage drug candidates.

Tampa General is launching the largest master facility plan in the hospital’s history to continue growing and innovating to meet the needs of the community and beyond for decades to come.

AB Science SA (Euronext - FR0010557264 - AB) today announced that its clinical trial with AB8939 in adult patients with relapsed/refractory acute myeloid leukemia (AML) has been approved by Health Canada.

Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, today announced positive preclinical data demonstrating that ELI-005, a protein subunit vaccine containing the lymph node-targeted Amphiphile-CpG adjuvant (AMP-CpG), induces potent cellular and humoral immunity to SARS-CoV-2 at the 2021 Vaccines Summit.

Synlogic, a clinical stage company bringing the transformative potential of synthetic biology to medicine, announced that it has commenced an underwritten public offering of its common stock.

Newtopia Inc. today announced that Jeff Ruby , Founder and CEO, will participate in the Benzinga Healthcare Conference taking place virtually on September 30, 2021 .

Agilent Technologies, Inc. (NYSE: A) today announced that a quarterly dividend of 19.4 cents per share of common stock will be paid on Oct. 27, 2021, to all shareholders of record as of the close of business on Oct. 5, 2021.

Rosalind Franklin University of Medicine and Science is announcing a research collaboration with Aptinyx, a clinical-stage biopharmaceutical company, to support the development of new therapeutics for brain and central nervous system disorders.